JAOA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

JAOA • Vol 104 • No 9_suppl • September 2004 • 14-16
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spratt, K. A.
Right arrow Articles by Denke, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spratt, K. A.
Right arrow Articles by Denke, M. A.

Utility of Currently Available Modes of Therapy in Reaching Lipid Goals

Kelly Anne Spratt, DO; Margo A. Denke, MD

University of Pennsylvania Health System, Cardiovascular Division, Philadelphia Heart Institute in Pennsylvania (Dr Spratt) and The University of Texas Health Science Center at San Antonio (Dr Denke).
Dr Spratt is on the speakers bureau for Merck & Co, Pfizer Inc, and AstraZeneca Pharmaceuticals LP. Dr Denke is on the advisory board of Merck/Schering–Plough Pharmaceuticals and on the speakers bureau for Merck & Co and Merck/Schering–Plough Pharmaceuticals. She also is an advisor and a coauthor on the Ezetimibe Add-on to Statin for Effectiveness (EASE) trial.

Address correspondence to Kelly Anne Spratt, DO, Clinical Assistant Professor of Medicine, University of Pennsylvania Health System, Cardiovascular Division, Philadelphia Heart Institute, Second Floor, 39th & Market Streets, Philadelphia, PA 19104.E-mail: kspratt{at}uphs.upenn.edu

The National Cholesterol Education Program Adult Treatment Panel III lipid management guidelines emphasize the importance of matching the intensity of lipid modification therapy to each patient's risk of coronary heart disease. For many patients who are at low risk, nonpharmacologic interventions such as diet, exercise, and smoking cessation can be effective lipid-lowering strategies. However, many patients require the addition of drug therapy to achieve lipid targets. Currently available lipid-modifying drugs include bile acid sequestrants, fibrates, nicotinic acid, cholesterol absorption inhibitors, and statins. In addition, nonprescription agents such as plant stanols and sterols are available to modify plasma lipid levels. These agents can be used individually or coadministered to achieve lipid goals.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Osteopathic Association.